Completed PHASE1 INTERVENTIONAL 3-arm NCT00929955

Role of Anti-Inflammatory Agents in Patients With Schizophrenia

Study of Role of Anti-Inflammatory Agents in Patients With Schizophrenia

Sponsor: Dow University of Health Sciences

Conditions Psychosis Not Otherwise Specified Schizoaffective Disorder Schizophrenia Schizophreniform Disorder

Interventions Ondansetron Placebo Simvastatin

Updated 7 times since 2017 Last updated: Aug 2, 2019 Started: Jun 30, 2009 Primary completion: Sep 30, 2009 Completion: Sep 30, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Psychosis Not Otherwise Specified and Schizoaffective Disorder and is currently completed. Dow University of Health Sciences leads this study, which shows 7 recorded versions since 2009 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Sep 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Unknown Status → Completed
Jun 2018 — Sep 2019 [monthly]

Unknown Status PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Unknown Status PHASE1
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE1

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Dow University of Health Sciences
Karwan e Hayat
Pakistan Institute of Living and Learning

Data source: Pakistan Institute of Living and Learning

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan